Benzinga | Mar 10, 2021 09:05AM EST

Virpax Signs Agreement With Charles River Laboratories To Initiate Investigational New Drug Enabling Studies For Epoladerm

BERWYN, PA / ACCESSWIRE / March 10, 2021 / Virpax(r) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that it has signed an agreement with Charles River Laboratories to initiate preclinical studies of Epoladerm(tm), Virpax's proprietary, patented, anti-inflammatory topical spray film delivery technology for acute musculoskeletal pain. Under the terms of this agreement, Charles River Laboratories will perform seven preclinical animal studies including method, dosage, and toxicity as part of the required U.S. Food and Drug Administration ("FDA") enabling trials for an Investigational New Drug Application ("IND") for Epoladerm(tm).